Clinical trials · Riverside–San Bernardino, CA
Liver Diseases clinical trials in Riverside–San Bernardino
We’re tracking 26 recruiting liver diseases studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT07165028RecruitingPhase 3
Study of new drugs for fatty liver with scarring
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Riverside, CaliforniaAges 18 years+ - NCT03228290Recruiting
Liver transplant care study using patient function check
This study looks at how people with liver disease function day to day, especially around liver transplant care. It may help improve how doctors assess readiness and recovery needs.
Loma Linda, CaliforniaAges 18 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Rialto, CaliforniaAges 18 years+ - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Rialto, CaliforniaAges 18–75 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Rialto, CaliforniaAges 18–80 - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Rialto, CaliforniaAges 18 years+ - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Rialto, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Montclair, CaliforniaAges 18–75 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Covina, CaliforniaAges 18–75 - NCT06607458RecruitingPhase 2
Liver-focused chemo for metastatic colorectal cancer
This trial tests giving high-dose melphalan directly into the liver's blood supply, followed by standard cancer therapy, for people whose colorectal cancer has spread mainly to the liver. The goal is to see if this approach is safer and works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Fountain Valley, CaliforniaAges 1 day–17 years - NCT01403402Recruiting
Study of congenital muscle disease patients and their families
This trial collects health information from patients with certain inherited (genetic) muscle diseases and from their families. It may help researchers better understand the disease and improve care by learning what symptoms and treatments patients experience over time.
Lakewood, CaliforniaAges Any age - NCT07527910RecruitingPhase 2
Study of ALN-PNP with or without tirzepatide for fatty liver disease
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
Pasadena, CaliforniaAges 18–75 - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Pasadena, CaliforniaAges 18–70 - NCT06068491Recruiting
Veteran-centered care for advanced liver disease
This study tests a new way of caring for veterans with advanced liver disease. It aims to help you manage your condition better and improve your quality of life.
Long Beach, CaliforniaAges 18–80 - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Los Angeles, CaliforniaAges 18–75 - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Los Angeles, CaliforniaAges 2–25 - NCT05744713Enrolling by invitation
Study of adults with long-term liver disease using health records
This observational study looks at adults with chronic liver disease (including cirrhosis) to better understand how people are managed and how they feel over time. Because it does not change your treatment, it may help researchers improve care and patient support.
Los Angeles, CaliforniaAges 18 years+ - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
Los Angeles, CaliforniaAges 18–75 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Los Angeles, CaliforniaAges 18–75 - NCT00345930Recruiting
Study of liver injury after medicines or supplements
This study looks at people (including children over age 2) who develop liver injury that may be caused by a drug or a complementary/alternative medicine (CAM) product. It helps doctors better understand what causes the injury and how to evaluate it.
Los Angeles, CaliforniaAges 2 years+ - NCT04613921Recruiting
Liver transplant study for severe worsening liver failure
This study looks at when liver transplant is offered and what outcomes happen in people with cirrhosis who have severe “acute-on-chronic” worsening. It may help doctors decide which patients benefit most from transplant and improve care after listing or not listing.
Los Angeles, CaliforniaAges 18–80 - NCT04937868Recruiting
Guiding CT scans for belly and pelvis injuries after blunt trauma
This study looks at how to make a better decision tool for when to order a CT scan of the belly and pelvis after a blunt injury in the emergency department. It aims to help clinicians choose the right patients for imaging during the first evaluation.
Los Angeles, CaliforniaAges Any age
Hear when a new Liver Diseases trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Liver Diseases trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting liver diseases studies listed above.
- GSK Investigational Site · 5 studies
- Ark Clinical Research · 4 studies
- California Liver Research Institute · 4 studies
- Clinnova Research Solutions · 3 studies
- University of California, Los Angeles (UCLA) · 3 studies
- Velocity Clinical Research, Huntington Park · 3 studies
- Catalina Research Institute · 2 studies
- Inland Empire Clinical Trials · 2 studies
What taking part in a liver diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting liver diseases studies in California.
Common questions
- Are there liver diseases clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 26 recruiting liver diseases studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a liver diseases study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a liver diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New liver diseases studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.